ThE uSE of AbErrAnT METhylATEd gEnES SEPT9 And VIM for clInIcAl dIAgnoSIS of colorEcTAl cAncEr

Cover Page

Cite item

Full Text

Abstract

Definition of epigenetic disorders is important for early diagnosis of colorectal cancer. To obtain a model of diagnostic test system with high sensitivity and specificity, we determined the frequency of methylation in SEPT9 and VIM genes. Epigenetic events also were compared with mutations in the RAS family genes. It was confirmed the presence of aberrant methylation in SEPT9 and VIM genes in tumor cells. DNA of tumor samples was significantly more methylated than samples with DNA from adjacent tissue (P = 8,67E-19 for SEPT9 gene and P=8,68E-19 for VIM gene). In the group of patients carried mutations in KRAS or NRAS genes tumor DNA significantly more methylated in gene SEPT9 (P = 0.0018), in contrast to the tumor DNA from patients not carried mutations. We have demonstrated that the combined use of methylation markers can improve the sensitivity of the test systems used in the diagnostics of colon cancer.

About the authors

O I Brovkina

ЦБМТ ФГБУ ФНКЦ ФМБА России

Email: brov.olia@gmail.com
кандидат биологических наук, старший научный сотрудник лаборатории генетики ЦБМТ ФГБУ ФНКЦ ФМБА России

M G Gordiev

ЦБМТ ФГБУ ФНКЦ ФМБА России

Email: marat7925@gmail.com
заведующий Молекулярно-диагностической лабораторией ГАУЗ «Республиканский клинический онкологический диспансер МЗ Республики Татарстан»

D S Khodyrev

ЦБМТ ФГБУ ФНКЦ ФМБА России

Email: DmKh008@gmail.com
кандидат биологических наук, старший научный сотрудник лаборатории генетики ЦБМТ ФГБУ ФНКЦ ФМБА России

A G Nikitin

ЦБМТ ФГБУ ФНКЦ ФМБА России

Email: avialn@gmail.com
кандидат биологических наук, заведующий лабораторией генетики ЦБМТ ФГБУ ФНКЦ ФМБА России

A V Averyanov

ФГБУ ФНКЦ ФМБА России

Email: averyanovav@mail.ru
заведующий отделением пульмонологии ФНКЦ ФМБА России,руководитель Центра биомедицинских технологий, д.м.н.

References

  1. Jones P.A., Baylin S.B. 2007. The Epigenomics of Cancer. Cell. 2007;128: 683-692.
  2. Wild N., Andres H., Rollinger W., et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res. 2010;16(24):6111-21. doi: 10.1158/1078-0432.CCR-10-0119.
  3. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37: 646-650.
  4. Russell S.E.H., Hall P.A. Do septins have a role in cancer? Br. J. Cancer. 2005;93: 499-503.
  5. Kinoshita M., Noda M. Roles of septins in the mammalian cytokinesis machinery. Cell Struct Funct. 2001;26: 667-670.
  6. Joo E., Tsang C.W., Trimble W.S. Septins: traffic control at the cytokinesis intersection. Traffic Cph. Den. 2005;6: 626-634.
  7. McDade S.S., Hall P.A., Russell S.E.H. Translational control of SEPT9 isoforms is perturbed in disease. Hum Mol Genet. 2007;16: 742-752.
  8. Estey M.P., Di Ciano-Oliveira C., Froese C.D., Bejide M.T., Trimble W.S. Distinct roles of septins in cytokinesis: SEPT9 mediates midbody abscission. J Cell Biol. 2010;191: 741-749.
  9. Zou H., Harrington J.J., Shire A.M., et al. Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2686-96.
  10. Brenner D.E., Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst. 2005; 97: 1107-9.
  11. Schneider K.U., Dietrich D., Fleischhacker M., et al. Correlation of SHOX2 Gene Amplification and DNA Methylation in Lung Cancer Tumors. BMC Cancer. 2011 Mar 22;11:102. doi: 10.1186/1471-2407-11-102.
  12. Mikeska T., Craig J.M. DNA Methylation Bio-markers: Cancer and Beyond. Genes. 2014;5:821-864.
  13. Linardou H., Briasoulis E., Dahabreh I.J., et al. 2011. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat. Rev. 2011;37: 221-233.
  14. Ying H.-Q., Wang F., He B.-S., et al. The involvement of Kras gene 3’-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis. OncoTargets Ther. 2014;7: 1487-1496.
  15. Кит О.И., Водолажский Д.И., Дваденко К.В., et al. 2016. Аберрантное метилирование промоторных участков генов APC, CDH13 и MGMT у больных колоректальным раком. Сибирский Онкологический Журнал. 2016;15: 48-55.
  16. Cerottini J.P., Caplin S., Saraga E., Givel J.C., Benhattar J. The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg. 1998;175: 198-202.
  17. Беляева А.В. Мутации в гене K-RAS у больных колоректальным раком. Автореф. дис. ...канд. мед. наук. Спб.: 2012.- 27 с.

Copyright (c) 2016 Brovkina O.I., Gordiev M.G., Khodyrev D.S., Nikitin A.G., Averyanov A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies